PTC THERAPEUTICS, INC. (PTCT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PTCT currently has 8.29M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 2.37% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 8.3M shares outstanding |
8.3M | 0 |
| Nov 04, 2025 |
10-Q filing | 78.5M shares outstanding |
78M | 0 |
| Aug 07, 2025 |
10-Q filing | 78.2M shares outstanding |
78M | 0 |
| May 06, 2025 |
10-Q filing | 78.1M shares outstanding |
78M | 0 |
| Feb 27, 2025 |
10-K filing | 76.8M shares outstanding |
77M | 0 |
| Nov 07, 2024 |
10-Q filing | 76.9M shares outstanding |
77M | 0 |
| Aug 08, 2024 |
10-Q filing | 76.7M shares outstanding |
77M | 0 |
| Apr 25, 2024 |
10-Q filing | 76.5M shares outstanding |
76M | 0 |
| Feb 29, 2024 |
10-K filing | 74.8M shares outstanding |
75M | 0 |
| Oct 26, 2023 |
10-Q filing | 75.4M shares outstanding |
75M | 0 |
| Aug 03, 2023 |
10-Q filing | 74.7M shares outstanding |
75M | 0 |
| Apr 27, 2023 |
10-Q filing | 73.7M shares outstanding |
74M | 0 |
| Feb 21, 2023 |
10-K filing | 71.7M shares outstanding |
72M | 0 |
| Oct 27, 2022 |
10-Q filing | 71.7M shares outstanding |
72M | 0 |
| Aug 04, 2022 |
10-Q filing | 71.4M shares outstanding |
71M | 0 |
| May 03, 2022 |
10-Q filing | 71.2M shares outstanding |
71M | 0 |
| Feb 22, 2022 |
10-K filing | 70.5M shares outstanding |
70M | 0 |
| Oct 28, 2021 |
10-Q filing | 70.7M shares outstanding |
71M | 0 |
| Jul 29, 2021 |
10-Q filing | 70.6M shares outstanding |
71M | 0 |
| May 04, 2021 |
10-Q filing | 70.4M shares outstanding |
70M | 0 |
| Feb 25, 2021 |
10-K filing | 70.3M shares outstanding |
70M | 0 |
| Oct 29, 2020 |
10-Q filing | 67.8M shares outstanding |
68M | 0 |
| Aug 05, 2020 |
10-Q filing | 67.7M shares outstanding |
68M | 0 |
| Jun 04, 2020 |
8-K filing: PTC Therapeutics acquired Censa Pharmaceuticals and issued 845,365 shares of common stock to Censa securityholders as part of the upfront consideration for the merger. |
62M | 0 |
| May 06, 2020 |
8-K filing: PTC Therapeutics, Inc. entered into an agreement to acquire Censa Pharmaceuticals Inc. through a merger, involving cash and PTC Therapeutics common stock. |
62M | 0 |
| Apr 30, 2020 |
8-K filing: PTC Therapeutics, Inc. issued 2,723,826 shares of its common stock and paid $36,881,009 to certain former equityholders of Agilis Biotherapeutics, Inc. in exchange for the cancellation and forfeiture of their rights to receive certain milestone-based contingent payments under the Merger Agreement. |
51M | 0 |
| Apr 30, 2020 |
10-Q filing | 61.9M shares outstanding |
62M | 0 |
| Mar 02, 2020 |
10-K filing | 50.6M shares outstanding |
51M | 0 |